Alternative Epinephrine Auto-Injector

Submitted to:
Dr. Michael Whitt, Professor
California Polytechnic State University, San Luis Obispo
1 Grand Avenue San Luis Obispo, CA 93405

Prepared by:
Tara Howard, Biomedical Engineering Undergraduate
Uriel Nieves-Cruz, Biomedical Engineering Undergraduate
Joshua Wong, Biomedical Engineering Undergraduate
California Polytechnic State University, San Luis Obipso

Date Submitted:
1 June 2020

1

Statement of Confidentiality
The complete senior project report was submitted to the project advisor and sponsor. The
results of this project are of a confidential nature and will not be published at this time.
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Statement of Disclosure
Since this project is a result of a class assignment, it has been graded and accepted as
fulfillment of the course requirements. Acceptance does not imply technical accuracy or
reliability. Any use of information in this report is done at the risk of the user. These risks may
include catastrophic failure of the device or infringement of patent or copyright laws. California
Polytechnic State University at San Luis Obispo and its staff cannot be held liable for any use or
misuse of the project.
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Statement of Work
Executive Summary
Every three minutes, a person is committed to the emergency room as a result of a food allergy
in the United States. Over the period of a year, roughly 200,000 people require medical
attention for these severe allergic reactions as a result of anaphylaxis [1]. Anaphylaxis (also
known as anaphylactic shock) causes your immune system to release a flood of chemical
substances, including histamine from cells in the blood and tissues where they are stored.
These released chemicals are caused by the interaction between an allergic antibody
Immunoglobulin E (IgE) and the substance (allergen) causing anaphylactic shock [2]. Where
even trace amounts of the allergen can cause a reaction of hives, swelling, and lowered blood
pressure. The immediate treatment of anaphylactic shock consists of epinephrine typically
delivered by an auto-injector. The most common adrenaline auto-injector is the EpiPen by
Mylan which was prescribed to an estimated 3.6 million Americans in 2015 [7]. The price of an
EpiPen is around $650 for a two-pack which has gone up from $93.88 from 2007 of an increase
of 500%. Due to the dramatic price increase, many consumers are forced to hold onto their
expired EpiPens at risk of anaphylactic shock as they can not afford a new prescription. As a
result, the purpose of our senior design project is to create an affordable alternative to the
EpiPen that will act as an acceptable generic in the current market.

Introduction
Project: Alternative Epinephrine Injector started as a solution for Bianca Aleman’s little brother
however the scope has evolved to include the many millions of individuals across the world who
struggle with a life-threatening allergen. The stakeholders of this project are Cal Poly and Dr.
Michael D. Whitt. Our goals are the following:
● Develop a foolproof method of injection that consistently delivers a dosage of
epinephrine
● Be equal or less than the current size of an EpiPen (6 in)
● Be easy to transport or store when not-in-use
● Create an isolated environment where the epinephrine will not be denatured due to
environmental changes (e.g. temperature, light sensitivity, etc.)
● Class II FDA Medical Device
● Deliver a fully functioning prototype of an alternative epinephrine auto-injector
● Stay within a budget of $200 - $700
● Do not infringe on Mylan or Kaleo’s current patent

Background
Patients who suffer from severe allergic reactions causing anaphylaxis utilize the medication
epinephrine, via a subcutaneous injection, to improve their symptoms and reverse swelling in
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the throat to open up breathing. Currently, Mylan’s EpiPen Auto-Injectors and EpiPen Jr. nearly
corner the market for epinephrine injection products. These Mylan products, for non-insured
individuals, can cost between $300 and $630, which is a 500 percent price increase since 2007
[6]. Other companies have released similar products, the Adrenaclick, Auvi-Q, and Symjepi, as
well as some generic name products, but all of which are still highly expensive (the cheapest
priced at $110, without insurance). From our research, we found a new product would impact a
large market, with 32 million Americans suffering from food allergies, 200,00 of which requiring
emergency medical care, and most of which being highly dissatisfied with the current options
available for treatment [1].
Anaphylaxis is a life-threatening condition, brought on by serious allergic reactions. At-risk
patients are typically prescribed epinephrine auto-injectors; however a large proportion of
patients fail to fill their prescriptions due to high prices, which is due to the lack of regulations on
price, given it is not classified as a preventative medicine [8]. Lack of patient adherence is a
serious concern, as prompt facilitation of the medication is necessary for reducing
hospitalizations and fatalities [3]. While the benefits of using epinephrine auto-injectors highly
outweighs the risks, it is important to note them. When using auto-injectors, specifically when
used by children, accidental injections of epinephrine to people not in anaphylactic shock have
been known to occur, which requires medical attention due to the possibility of tissue death due
to blood flow reduction. As well, many patients use expired devices due to their high cost. While
some risks are associated with this practice, they are still effective and do not induce a higher
risk [6].
A study performed on the importance of usability of auto-injectors as treatment for anaphylaxis
showed that EpiPen Jr.’s were inferior to the design of the Auvi-Q [5]. The Auvi-Q, produced by
Kaleo, is shaped more closely to a small box compared to the EpiPen Jr.’s near cylindrical,
pen-shaped design. This study was evaluated by studying untrained adults’ completion of
injection tasks on child-sized mannequins, and showed a far higher rate of accidental injection
(if needle had not been removed) when using the EpiPen Jr. and the when using the Auvi-Q, a
much higher rate of injection into the desired region was found.
Table 1. Current products on the market
Patent #

Potential Infringements

10,406,288

The specific parts in which comprises the delivery mechanism for an
auto-injector. The delivery mechanism’s drive members.

10,320,439

Utilizing a smartphone case as a housing for an epinephrine auto-injector

10,369,292

The plunger assembly for a fluid dispensing syringe, such as the one in an
auto-injector

10,525,206

The creation of an auto-injector that is not sufficiently unique from this
definition.
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10,500,337

The creation of an auto-injector utilizing a piston that is not sufficiently
different from this definition.

This device would most likely be classified as a class II device, per the FDA regulations for
medical devices. With this classification, to move to the market, the most critical regulation
would be the 21 CFR, most specifically the 21 CFR part 807 - the Pre-Market Notification
510(k). Once a prototype is developed, it may go into clinical trials in laboratory environments.
Next, it must be submitted for a pre-market notification to get FDA clearance. Once approval is
received, the device must stay in compliance for its lifetime.

Objectives
Problem Statement
● Develop and deliver an alternative epinephrine injector suitable as a replacement for the
market’s leading medical device.
Boundary Definition
● Explicitly includes:
○ Alternative epinephrine injector
○ Auto-injection mechanism
○ Safety mechanism
○ Isolated environmental chamber
■ Resists temperature fluctuations
■ Reduces exposure to light
● Explicitly does not include:
○ Infringement on current Mylan EpiPen patent or Kaleo Auvi-Q
■ Mylan: US Patent No. 7,794,432
■ Kaleo: US Patent No. 8,920,377
Summary of Customer Needs/Wants
● From information received in needs assessments with actual consumers, we found the
customers need a highly reliable and safe epinephrine auto-injector for use during
life-threatening anaphylactic shock.
● As well, we found customers wanted an alternative to the current market leaders
(EpiPen and Auvi-Q), in that they want a device that is smaller, more user-friendly, and
cheaper.
Product Specifications Matrix
● See ‘House of Quality’ document for in-depth analysis.
Specification Measurement
● See ‘Specification Development’ on page 13.
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High-Risk Specifications
● The high-risk specification we face is the injection mechanism as a drug auto-injector is
considered a class II medical device.

Project Management
The first stage of the design process is to create and identify how the auto-injector will deliver
the epinephrine into the subject. After the mechanism is designed, the environmental isolation
chamber which houses the epinephrine will need to be created as it will house and protect the
drug from potential environmental factors. Then, we can create a housing for both subunits
which covers the delivery mechanism and environmental chamber.
The project timeline and critical path will be delivered at a later date after the second revision of
our network diagram has been completed.
Special analysis techniques will be reviewed later as we approach a prototype.

Conclusion
The purpose of this statement of work is to finalize and confirm our project’s scope, explain the
background and market need for a new product, and detail our design process. In the coming
weeks, a shortlist of potential final design concepts can be expected. We ultimately plan to have
completed our research and design specifications by 2/18 and our final prototype design by 3/9.
Our written documentation of our product will be finalized by 3/15 so we can present our critical
design report on 3/16. We plan on using the rest of our time to manufacture, test, and finalize
our product as to have a design review poster presentation during the senior project exposition
by 6/6. Throughout the process we will strive to reach all of our deliverables on time while
maintaining a high-quality of work.
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Network Diagram

Figure 1a. Network Diagram including Critical and Non-Critical Tasks
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Figure 1b. Network Diagram and Critical Path
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Indications for Use
Our product is indicated for the relief of symptoms in patients who are experiencing
life-threatening anaphylactic shock due to consumption or exposure to allergens or any other
known or unknown triggers as judged by the patient themselves. The intended use of this
product is for immediate emergency procedure only. Further medical help should be sought and
notified right away.
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Budget
Our materials list for our budget is a living document that we will make alterations to as we
continue this project. Currently, our total project budget is $700; however, we aim to stay well
below this amount. It is presumed that the main allocation of our budget will be to 3D printing
materials to design the casing/housing of our auto-injector. The amount of filament needed may
fluctuate due to how many prototypes are printed.
Below is our current, non-exhaustive list for budgeting the materials necessary to complete our
project.

Figure 2: Preliminary list of materials along with the quantity and cost of each material to finish our prototype device.
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Customer Requirements
In order to define our customer requirements, we interviewed current carriers of similar
products, EpiPen and Auvi-Q, to determine what features of an auto-injection device were
necessary for our product. The customer requirements were portability, production cost, and
ease of use.
These three requirements can further be broken down into the following sub-categories:
1. Portability
a. Shape
b. Weight
c. Dimensions
2. Production Cost
a. Material Composition
b. Method of Manufacturing
c. Complexity of Device
3. Ease of Use
a. Design Efficiency
b. Design Efficacy
c. Affordability
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Specification Development
Before applying quantitative measurements to each of our customer requirements, we must first
define our specifications.
Shape - The two most seemingly desirable shapes are a cylindrical shape and a rectangular
box shape.
Weight: Our product must not exceed .15 pounds.
Dimensions- No larger than 3.4” x 2.3” x .5” for a rectangular box design. No larger than R.5” x
7” for a cylindrical design.
Material Composition: 3D-printing filament, adhesive, plastic, stainless steel, and glass.
Additional materials may be incorporated with further manufacturing.
Method of Manufacturing: The current method of manufacturing is to 3D-print a designed
apparatus shell to house the internal components of our device. The first devices will then be
assembled by hand.
Complexity of Device: To be reviewed.
Design Efficiency: Yield at least four products with the current budget provided.
Design Efficacy: Full dosage of medicine should be administered 100% of the time used.
Affordability: Each unit should be able to be manufactured in less than $60.
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TAM and Competitive Advantage
In the United States, 3.6 million people are prescribed EpiPens, and 300,000 emergency room
visits are reported per year for children under the age of 18 due to food allergies [8]. In 2018,
the U.S. market for EpiPens alone reached approximately US $750 million per year, and the
entire epinephrine auto-injector worldwide market is estimated to reach US $2.4 billion per year
by 2024 [4]. The Total Available Market for our product, if 100% of the available market is
achieved, would be equal to the worldwide market, and thus be very vast.
Our competitive advantage over the two top-selling epinephrine auto-injectors includes our
product having a less bulky, more user-friendly, and more practical design. As well, while Mylan
(the owner of the EpiPen brand) had a near monopoly on the market and thus continuously
increased their prices, we would pledge to not flagrantly pad our profit margins at the expense
of patients' ability to have access to the product. While it would take time to switch lifetime users
of EpiPens and Auvi-Qs over to our product, we believe all users who struggle to afford the
highly expensive auto-injectors would make an immediate switch.
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Intellectual Property Assessment
In order to not infringe on any pre-existing patents regarding the design of our auto-injection
device, it is important to be knowledgeable of exactly what patents are currently on the market.
Below in Table 2 is a list of three current patents and three patent applications which have some
claims which we could have potentially infringed upon had we not known them.
Table 2: List of patents and current claims on the market.

Patent Name

Patent No.

Patent(P)/
Applicant(A)

Claim

Claim
Addressed

Delivery
mechanism for
an autoinjector

10,406,288

P

Dual drive injection
mechanism wherein
two drives are
configured to each
load their own
mechanism to 1)
drive the needle into
the leg and 2) drive
medicine through the
needle.

Design Change
necessary. Perhaps
a three drive
composition or a
way to manufacture
two components to
be driven by the
same mechanism.

Medical Device
Case

10,320,439

P

A two pocket
smartphone case
where an epinephrine
injection mechanism
can be easily
inserted into one and
medication tablets
can be stored within
the other.

Either do not
incorporate a
smartphone case
into our design or
instead make the
auto injector
inseparable from the
phone case.

Syringe plunger
assemblies

10,369,292

P

A specific design for
an integrated plunger
and plunger rod
which can propel
fluid as well as a
stopping mechanism
for the plunger itself.

Do not incorporate
this plunger design
within our device.

Autoinjector
carrier

20190381236

A

A certain housing
design for an
autoinjector within
which the
autoinjector can be
easily removed via
pushing up from the
bottom.

Design a different
housing case for our
product. Perhaps
one that uses the
force of gravity to
slide our device out
of--no human forces
necessary.

Wearable
Medication
Delivery Device

20190374714

A

A method,

comprising:
maintaining a needle
driver of a needle
actuator under load
of a spring by mating
a first key with a first
notch in the needle

Design our product
with a manual
stimulation
necessary for
needle release.
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driver and mating a
second key with a
second notch in the
needle driver; and
deploying a needle
coupled to the needle
driver into skin of a
person.

Methods,
Systems and
Devices for
administering
medication

20180078710

A

A medication
delivery device
comprising of a
syringe, flange,
syringe barrel, and
plunger.

Inhibit the
withdrawal of blood
via the needle
during its removal
from the patient.

17

Conjoint Analysis
Table with your Factors and Levels

Factor

Level 1

Level 2

Cost (w/o insurance / w/
insurance)

$360

$650

Dimensions

Cube

Cylinder

3.37” x 2.125” x .5”

R .5” x 6”

Gas-powered

Spring-powered

Injection Mechanism

Listing of Conjoint Cards

Card #

Cost

Dimensions/
Portability

Injection
Mechanism

1

$360

Cube

Gas-powered

3.37” x 2.125” x 0.5”
2

$360

Cylinder

Spring-powered

R .5” x 6”
3

$650

Cube

Spring-powered

3.37” x 2.125” x 0.5”
4

$650

Cylinder
R .5” x 6”

Gas-powered
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Card #

Cost

Dimensions

Delivery
Mechanism

1

0

0

0

2

0

1

1

3

1

0

1

4

1

1

0

Ranking: (Best-to-worst)
1.
2.
3.
4.
5.
6.
7.
8.
9.

2143
2143
2134
3421
2413
2143
2431
2413
2314

Statistical Analysis

19
A brief discussion on which factors you believe will be important to the success of this product
based on the information obtained from your classmates.
a.

Which

factors matter to my customer (at given confidence).

As the p-values are greater than .05, we fail to reject the null hypothesis indicating that
the result is statistically insignificant.
b.  How much those factors affect my customer attraction to using my product (via the
coefficients given).
Both cost and dimensions affect our customer attraction equally at a coefficient of .333
each. However, the method of injection mattered the least to our customers with a
coefficient of .111.
c.
How much those factors that matter explain the customer attraction (via r-squared or
coefficient of determination)
As our r-squared value is .047, this indicates that there is a very weak 3relationship
between the dependent variables and independent variables.
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Morphology
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Concept Evaluation
The front runner design we decided upon is a single spring injection mechanism with a button
actuator that would deliver the epinephrine into the patient. The injection mechanism delivers
the drug through means of a compressed spring that is coiled around the plunger and held in
place by the slightly wider top of the plunger which is then released when the button is pressed.
After the button has been pressed, the needle is then propelled forward as a result of the spring
force within the device and plunges itself into the patient. As the needle pierces the skin, a
rubber stopper slides backward revealing the injection hole. Once the injection hole has been
exposed, the drug is then injected into the patient as a result of the driving rod that pushes the
rubber stopper forward in the direction of the patient and thus driving the drug into the patient.
The model we have developed relies on the following equation for the force needed to inject the
solution (epinephrine) into the patient:
●

2

F = 32μL( Dd4 )( VT )
○
○

F = force required to inject the volume of a solution
μ = viscosity of the solution

○
○
○
○
○

L = length of the needle
D = inner diameter of the syringe’s barrel
d = inner diameter of the needle
V = volume of the solution
T = duration of time

This equation will assist us in determining the proper spring constant we need, and thus, the
spring we will utilize in our design. The needle selected is 1.5 millimeters in diameter, and it is
hypothesized that the exposed needle length will be approximately 16 millimeters. The diameter
of the barrel is 11 millimeters. A common concentration for epinephrine in solution is 1mg/1mL.
With the auto-injectors, even though 2mL of solution is stored, only 0.3 mL, and thus 0.3 mg of
epinephrine, are actually injected. Each 0.3 mL of solution contains 0.3 mg epinephrine, 1.8 mg
sodium chloride, 0.5 mg sodium metabisulfite, hydrochloric acid to adjust pH, and water for
injection. The pH range is 2.2 - 5.0.
The solution, if produced commercially, would be compressed with nitrogen to avoid oxidation,
but due to constraints we have, oxygen will be used to compress the solution for our prototype.
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Conceptual Model
The following CAD drawing models our design:

In developing the model, we determined that a double-spring epinephrine auto-injector would be
more complicated and introduced more modes of failure than a single-spring auto-injector.
Furthermore, in looking at the inspirations of different designs, it was made more apparent that
the Auvi-Q auto-injector would be more difficult to model as well due to the shape of the
auto-injector. A credit card-sized injector is much more compact of a design than a linear model.
The linear model can be most accurately related to that of an EpiPen or an AdrenaClick.
Further development would be impacted by the design/product that makes up the needle and
injection mechanism. The model can only be as small as the needle and its casing.
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Detailed Design
The following CAD assembly drawing shows further improvements upon our conceptual model:

Our design is made up of five main parts – the outer cylinder case, the button/locking
mechanism, the inner cylinder guard, the syringe, and the springs. Seen first here is the outer
cylinder case. This is one of our 3D printed parts and serves as a protective casing for the
auto-injector, as well as holds the button firmly in place. This piece is the largest of all of the
parts. The next part is the button/locking mechanism. When in place, the button sticks through a
hole in the top of the outer casing, while the “legs” attach to the pegs on the syringe. The legs
serve as a locking mechanism. When the button is depressed, the legs pan out slightly,
releasing the syringe from being “locked”. The inner cylinder guard is seen below, which
prevents the button from moving. Both the guard and the button will be 3D printed. The syringe
will be purchased, along with a needle. We will affix the pegs onto the syringe. Through
displacement of the spring a small amount of pressurized oxygen will be engaged to push on
the distal end of the drug compartment, pushing the drug through the needle and into the
patient. The needle will need to be manually removed from the leg. Lastly, compressed springs
not seen in this model are to be affixed to the back sides of both the syringe and the button,
which will provide the force necessary to puncture the skin. When the button releases the
syringe, the spring is capable of forcing the syringe to its full length which allows the needle to
be exposed, then forces the oxygen to push the drug out of the syringe. Small changes to the
overall design of our product can be made as we move forwards with the testing of our project,
but the overall function or our auto-injection device will remain the same.
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Prototype Manufacturing Plans
We hoped to begin our manufacturing in early April, but due to the COVID-19 crisis, we were
forced to change our project into a more formal research project, developing future
manufacturing and testing plans for the product. The majority of our prototype will be 3D-printed
based off of the solidworks designs which we have made. The parts manufactured in this way
will be the outer cylinder case, inner cylinder guard, the safety cap and the button/locking
mechanism. A series of springs and glue will be purchased to combine and assemble each of
the pieces of our device into one cohesive product. The actual needle and syringe of our
auto-injector is being purchased from a vendor and will be inserted within our device.
Our prior plan was that once we had manufactured our first prototype, we would test our product
for design flaws and failures. Upon reflection, the details of our design might change, but the
method of manufacturing will remain the same, 3D-print or purchase the parts that we need.
This process would be repeated until we have created a reliable, working device.
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Test Plans
Design of Experiments
We plan on testing our product in three key areas of the design: the needle, the syringe, and the
efficacy of the device. The first and most important test that we will perform will be to determine
the strength and failure points of the needle that we are using. Using the provided bend-stress
testing and shear stress equipment we plan on testing the limits which our needle can
experience before failure. This is important as we need to know if there will be any danger of the
needle shearing or bending upon insertion of the leg as that could lead to failure of medicine
injection or increased physical injury.
Our syringe portion will be tested by submerging the body of the syringe underwater. The
syringe should be air-tight, as it needs to hold pressurized air within it for a pressure gradient to
be used for administering our medication. If we see air bubbles leak from our syringe then we
know we will need to find a different syringe body to use.
The next test we are going to perform is to validate the effectiveness of our device as a whole.
We are planning on purchasing ballistic gel and testing our completed model on the gel. When
we can consistently achieve the correct drug dosage and ejection mechanism function then we
will be ready to submit a final product. An aqueous solution will be mixed to the same viscosity
as epinephrine during these tests as that will most closely model real life function.
Performance Metrics
●
●
●

Needle
○ Flex testing
Syringe Body
○ Air-tight sealing
Device Efficacy
○ Delivers full dosage 100% of the time
Pass Criteria

Fail Criteria

Needle Testing

Elastic modulus of 8 +/- .001
GPa

Elastic Modulus of 8 +/- .002
GPa

Syringe Body

No liquid found within the
syringe body

Liquid found within the
syringe body

Device Efficacy

Delivers 100% of dosage
found within the syringe body

Any dosage found within the
syringe body
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Sample Sizes
A sample size of 30 samples, n = 30, will be used for every study.
Expected Results
In the three-bend-test, we expect every needle to perform within the given passing parameters.
As each needle is made from the same material and size, there would be no difference in this
first test. In the second test, we hope that the syringe body is completely sealed off from the
surrounding environment. As the syringe bodies are bought from a qualified medical supplier,
we expect each body to pass. The hardest test we expect to pass is that of device efficacy. As
our fail criteria includes any remaining liquid within the chamber, if any remains, we would have
to rethink our design and conduct a revision. We hope for a passing rate greater than 95%.
Network Diagram
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Resources and Contingencies
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Conclusion and Discussion
Current injection-based methods for epinephrine delivery have been proven to be costly, bulky,
and frequently improperly used, which showcases the deep need and market for a new method
of epinephrine delivery - a spring powered, button operated auto-injector. Using concept
morphology and conjoint analysis coupled with a detailed array of customer requirements, our
team developed a final detailed 3D computer aided design to present to our peers and to our
stakeholders. Our design, while not sleeker than the most popularized device, the EpiPen,
would allow for a safer drug delivery mechanism by deferring accidental ‘sticks’ and reducing
the costs of manufacturing once in the mass production stage due to the simplicity of the
design. From our research, while the size of the injector was important to the patients, they
cared more highly about the safety and efficacy of the delivery method; therefore, it became our
chief point of improvement we wanted to hit.
Due to the ongoing COVID-19 crisis, after the presentation of our detailed designs, we had to
segway our aims for this project from creating a functional prototype to developing future
manufacturing and testing plans, all while compiling the information and data into a mock design
history file, given that we would no longer be able to 3D print our product, and thus hindering us
from producing a prototype. With that being said, the extra time available due to not spending
weeks creating a physical deliverable allowed us to develop a far more in-depth understanding
and explanation of the necessity, purpose, and desired outcomes of our future testing methods
we would use for a product. As well, the dramatic shift in focus of our project taught us hands-on
skills for overcoming massive setbacks in engineering settings.
We are confident that patients’ outcomes would increase positively, improper dosings would
decrease, and more non-patients would feel comfortable using our product compared to the top
competitors if our product was manufactured in the methods we proposed for future
manufacturing plans. Our current largest concern is ensuring the needle can be punctured even
through the thickest of clothing, but with an increase in gauge size of the needle and higher
spring constant, this can be established, Further clinical studies would be required to prove this,
but given our presumptions, product specifications, and testing, all of these goals are well within
reach. We wish we could have seen our design come into physical fruition; however, the
assurance we received from our research led us to feel wholeheartedly comfortable and in
support of our product.
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